

Case Study



The Case of Competitive Landscape & Go/No-go Clinical Trial Decision for a Big Pharma


The Purpose

To identify the probability of the success of a new antibody for Rheumatoid Arthritis.

About the Client

 **COMPANY**
Big Pharma

 **LOCATION**
Switzerland

 **THERAPEUTIC AREA**
Rheumatoid Arthritis


Client Requirement

To assess relative position on efficacy of its antibody against competitor marketed biologics for Rheumatoid Arthritis, big pharma partnered with Excelra to develop an MBMA friendly dataset by scientific custom curation of existing evidence on efficacy of marketed biologics for Rheumatoid Arthritis.


The Excelra Approach

- Defined project scope with PICOS methodology for conducting Systematic Literature Research in PubMed.
- Screened, Labelled and Developed a database for enabling further qualification and selection of relevant publications according to PICOS specifications.
- Additional references were identified following a thorough search across FDA drug labelling information and traditional meta-analysis publications. (119 sources identified)
- A customized clinical outcomes database was developed, capturing:
 - Clinical outcomes summary data (Time vs Response)
 - Patient population details (Baseline characteristics, prior and background therapy)
 - Interventions (Dose regimen)
 - Comparator (Dosage regimen)
 - Study design (Sample size)
- A rigorous 3-level Quality Control (QC) process was employed for database development.

Antibody vs. Etanercept



Antibody vs. Adalimumab



Excelra's Contribution






Excelra refined the in-house literature database (Clinical Trial outcomes Database) for Rheumatoid Arthritis, which included 37 Phase II & III studies describing 13474 patients, 75 Arms, 502 summary points.

The database was updated with each time-point which is data-digitized from the illustrative time course curve in each study.

It enabled the client to compare the new compound with the available compounds for Rheumatoid Arthritis.

The magnitude of response, its time course analysis from Excelra's databases showed that the antibody had lower chances of success as compared to competitive drugs: Etanercept and Adalimumab, owing to its inferior efficacy profile in RA.

Excelra's Service Portfolio

	Insights	Data
 Discovery	<ul style="list-style-type: none"> • Data Science Driven Drug Discovery • Target Identification • Target Dossier Services 	<ul style="list-style-type: none"> • Chemistry Curation Services • GOSTAR Structure Activity Relationship database
 Translational	<ul style="list-style-type: none"> • Biomarker Discovery • Drug Repositioning • Life Cycle Management • Systems Biology Informatics 	<ul style="list-style-type: none"> • Biology Curation Services • GOBIOM Biomarker intelligence database
 Clinical	<ul style="list-style-type: none"> • Precision Oncology Informatics • Clinical Pharmacology 	<ul style="list-style-type: none"> • Clinical Trial Outcomes Database
 Value Evidence	<ul style="list-style-type: none"> • Outcomes Research • Epidemiology Modelling • Economic Modelling • Value Evidence Communication 	<ul style="list-style-type: none"> • RWE & Big Data Realization • SLR & Meta-analysis
 Technology Solutions	<ul style="list-style-type: none"> • Enterprise Data Strategy • Enterprise Cloud Ops • Enterprise Digital Transformation 	

For more information, visit https://www.excelra.com/clinical/#clinical_trial



About Excelra

Excelra's data and analytics solutions empower innovation in life sciences across the value chain from discovery to market. The Excelra Edge comes from a seamless amalgamation of proprietary curated data assets, deep domain expertise and data science. The company's multifaceted teams harmonize and analyse large volumes of disparate unstructured data using cutting-edge technologies. We galvanize data-driven decisions to unlock operational efficiencies to accelerate drug discovery and development. Over the past 18 years, Excelra has been the preferred data and analytics partner to over 90 global clients, including 15 of the top 20 large Pharma.